<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="756">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955044</url>
  </required_header>
  <id_info>
    <org_study_id>MJN 8662</org_study_id>
    <nct_id>NCT01955044</nct_id>
  </id_info>
  <brief_title>PUFA Supplementation in Premature Infants</brief_title>
  <official_title>Early DHA Supplementation in Extremely Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NorthShore University HealthSystem Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if buccal administration of a concentrated
      formulation of long-chain polyunsaturated fatty acids (LCPUFA) can help to maintain
      docosahexaenoic acid (DHA) levels in extremely low birth weight (ELBW) infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, placebo controlled, double blind trial.

      Two doses of PUFA will be compared to placebo- a &quot;high&quot; dose and a &quot;low&quot; dose.

      ELBW infants will be enrolled into this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Long-chain Polyunsaturated Fatty Acid (LCPUFA) Levels</measure>
    <time_frame>2 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>LCPUFA levels will be measured at 2 weeks of life in extremely low birth weight (ELBW) infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LCPUFA Levels</measure>
    <time_frame>8 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>LCPUFA levels will be measured at 8 weeks of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolvin Levels</measure>
    <time_frame>8 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resolvin, a metabolite of LCPUFA, will be measured at 8 weeks of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolvin Levels</measure>
    <time_frame>2 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>resolvin, a metabolite of LCPUFA, will be measured at 2 weeks of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Premature, Extremely Low Birth Weight Infants</condition>
  <condition>Polyunsaturated Fatty Acid Levels</condition>
  <arm_group>
    <arm_group_label>&quot;high&quot; dose LCPUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;low&quot; dose LCPUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LCPUFA supplement</intervention_name>
    <arm_group_label>&quot;high&quot; dose LCPUFA</arm_group_label>
    <arm_group_label>&quot;low&quot; dose LCPUFA</arm_group_label>
    <other_name>PUFA supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a) Premature infant born at gestational age less than 34 weeks

          -  b) Birth weight less than 1000 grams

          -  c) Legally authorized representative is able to provide written informed consent
             within the first 72 hours of life, prior to the performance of an protocol-specified
             evaluations or procedures

        Exclusion Criteria:

          -  a) infants with known metabolic disorder

          -  b) infants with known congenital gastrointestinal anomaly

          -  c) infants who are deemed to be inappropriate for enrollment per attending
             neonatologist
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Caplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 26, 2016</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <firstreceived_results_date>February 26, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem Research Institute</investigator_affiliation>
    <investigator_full_name>Brandy Frost</investigator_full_name>
    <investigator_title>Attending Neonatologist, Clinician Educator</investigator_title>
  </responsible_party>
  <keyword>neonatal prematurity</keyword>
  <keyword>infant, extremely low birth weight</keyword>
  <keyword>fatty acids, polyunsaturated</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>&quot;High&quot; Dose LCPUFA</title>
          <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="P2">
          <title>&quot;Low&quot; Dose LCPUFA</title>
          <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>&quot;High&quot; Dose LCPUFA</title>
          <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="B2">
          <title>&quot;Low&quot; Dose LCPUFA</title>
          <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.
placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long-chain Polyunsaturated Fatty Acid (LCPUFA) Levels</title>
        <description>LCPUFA levels will be measured at 2 weeks of life in extremely low birth weight (ELBW) infants</description>
        <time_frame>2 weeks of life</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 subjects died prior to having 2 week levels drawn, from causes unrelated to study.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;High&quot; Dose LCPUFA</title>
            <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
          </group>
          <group group_id="O2">
            <title>&quot;Low&quot; Dose LCPUFA</title>
            <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.
placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Long-chain Polyunsaturated Fatty Acid (LCPUFA) Levels</title>
            <description>LCPUFA levels will be measured at 2 weeks of life in extremely low birth weight (ELBW) infants</description>
            <units>weight % (g/100g)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>2 week DHA levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.45" lower_limit="4.36" upper_limit="5.16"/>
                  <measurement group_id="O2" value="4.02" lower_limit="3.96" upper_limit="4.77"/>
                  <measurement group_id="O3" value="5.27" lower_limit="4.75" upper_limit="5.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 week ARA (arachidonic acid) levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.3" lower_limit="18.91" upper_limit="21.34"/>
                  <measurement group_id="O2" value="19.3" lower_limit="17.64" upper_limit="22.54"/>
                  <measurement group_id="O3" value="21.58" lower_limit="20.2" upper_limit="23.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LCPUFA Levels</title>
        <description>LCPUFA levels will be measured at 8 weeks of life.</description>
        <time_frame>8 weeks of life</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>&quot;High&quot; Dose LCPUFA</title>
            <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
          </group>
          <group group_id="O2">
            <title>&quot;Low&quot; Dose LCPUFA</title>
            <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.
placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>LCPUFA Levels</title>
            <description>LCPUFA levels will be measured at 8 weeks of life.</description>
            <units>wt% (g/100g)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>8 week DHA levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.52" lower_limit="4.45" upper_limit="7.08"/>
                  <measurement group_id="O2" value="5.58" lower_limit="5.49" upper_limit="6.96"/>
                  <measurement group_id="O3" value="6.75" lower_limit="5.22" upper_limit="7.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8 week ARA levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.79" lower_limit="17.77" upper_limit="22.99"/>
                  <measurement group_id="O2" value="19.9" lower_limit="18.3" upper_limit="21.06"/>
                  <measurement group_id="O3" value="22.21" lower_limit="19.05" upper_limit="23.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolvin Levels</title>
        <description>Resolvin, a metabolite of LCPUFA, will be measured at 8 weeks of life.</description>
        <time_frame>8 weeks of life</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolvin Levels</title>
        <description>resolvin, a metabolite of LCPUFA, will be measured at 2 weeks of life.</description>
        <time_frame>2 weeks of life</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>&quot;High&quot; Dose LCPUFA</title>
          <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="E2">
          <title>&quot;Low&quot; Dose LCPUFA</title>
          <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.
LCPUFA supplement</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>Baby died from NEC, deemed unrelated to study substance</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>spontaneous bowel perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>severe respiratory failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brandy L Frost</name_or_title>
      <organization>NorthShore University HealthSystem</organization>
      <phone>847-570-2033</phone>
      <email>bfrost@northshore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
